Literature DB >> 12941787

Level of an advanced glycated end product is genetically determined: a study of normal twins.

R David G Leslie1, Huriya Beyan, Pam Sawtell, Bernard O Boehm, Tim D Spector, Harold Snieder.   

Abstract

Reducing sugars react with amino groups in proteins, lipids, and nucleic acids to produce advanced glycation end products (AGEs), including N(epsilon)-carboxymethyl lysine (CML), which have been implicated in oxidative stress and vascular damage. The aim of this study was to determine whether genetic factors influence serum CML levels in normal subjects. We performed a classical twin study of CML in healthy nondiabetic female twins, 39 monozygotic and 45 dizygotic pairs, aged 21-74 years. Serum CML levels were estimated by enzyme-linked immunosorbent assay. Twin correlations (r) for serum CML levels were higher in monozygotic (r = 0.71) compared with dizygotic (r = 0.50) twin pairs, suggesting a substantial genetic effect and confirmed by quantitative genetic model fitting. Additive genetic effects (heritability) explained 74% (95% CI 58-84) of population variance in CML. Heritability (%) of fasting glucose (51%) and HbA(1c) (62%) could not explain CML heritability, which was not associated with them. CML levels are, therefore, predominantly genetically determined and independent of genes influencing fasting glucose or HbA(1c). Thus familial, largely genetic factors influence AGE implicating these glycoxidation products in the genetic contribution to macro- and microvascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941787     DOI: 10.2337/diabetes.52.9.2441

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  21 in total

Review 1.  Targeting advanced glycation with pharmaceutical agents: where are we now?

Authors:  Danielle J Borg; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-07-09       Impact factor: 2.916

2.  Genetic analysis of advanced glycation end products in the DHS MIND study.

Authors:  Jeremy N Adams; Laura M Raffield; Susan E Martelle; Barry I Freedman; Carl D Langefeld; J Jeffrey Carr; Amanda J Cox; Donald W Bowden
Journal:  Gene       Date:  2016-02-23       Impact factor: 3.688

Review 3.  Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications.

Authors:  R David G Leslie; Robert M Cohen
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

4.  Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.

Authors:  Helen Vlassara; Jaime Uribarri; Weijing Cai; Susan Goodman; Renata Pyzik; James Post; Fabrizio Grosjean; Mark Woodward; Gary E Striker
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-29       Impact factor: 8.237

5.  Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer.

Authors:  Zhigang Duan; Guoqing Chen; Liang Chen; Rachael Stolzenberg-Solomon; Stephanie J Weinstein; Satu Mannisto; Donna L White; Demetrius Albanes; Li Jiao
Journal:  Int J Mol Epidemiol Genet       Date:  2014-10-22

6.  Correlation of advanced glycation endproducts estimated from skin fluorescence in first-degree relatives: the impact of adjustment for skin pigmentation.

Authors:  Eileen A Báez; Shreepal Shah; Dania Felipe; John Maynard; Stuart Chalew
Journal:  J Diabetes Sci Technol       Date:  2014-11-18

Review 7.  Oxidative Stress in Alzheimer's Disease: Should We Keep Trying Antioxidant Therapies?

Authors:  Michelli Erica Souza Ferreira; Amanda Soares de Vasconcelos; Thyago da Costa Vilhena; Thiago Leite da Silva; Aline da Silva Barbosa; Antonio Rafael Quadros Gomes; Maria Fani Dolabela; Sandro Percário
Journal:  Cell Mol Neurobiol       Date:  2015-01-24       Impact factor: 5.046

Review 8.  Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Authors:  Sherman S Leung; Josephine M Forbes; Danielle J Borg
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

9.  Use of human vascular tissue microarrays for measurement of advanced glycation endproducts.

Authors:  Marc K Halushka; Elizabeth Selvin; Jie Lu; Anne M Macgregor; Toby C Cornish
Journal:  J Histochem Cytochem       Date:  2009-02-16       Impact factor: 2.479

10.  Advanced glycation end products: Key players in skin aging?

Authors:  Paraskevi Gkogkolou; Markus Böhm
Journal:  Dermatoendocrinol       Date:  2012-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.